Today’s Reports on Biotech Movers Ariad Pharmaceuticals and Amicus Therapeutics

NEW YORK, NY / ACCESSWIRE / December 21, 2016 / After many years of impressive gains for investors the Biotech Industry has experienced downward pressure in 2016. The iShares NASDAQ Biotechnology Index ETF (IBB) is down over 20 percent year-to-date, while the broader indexes, the Dow Jones and the S&P 500, have posted gains of 14.6 percent and 11.1 percent, respectively, year-to-date. In 2015, the iShares NASDAQ Biotechnology Index ETF (IBB) posted an overall gain of 11.5 percent, with a sharp sell-off following its peak in late July 20 2015 till end of year. The S&P 500 Index posted an overall loss of 0.73 percent in 2015.

Register with us now for your free membership and gain access to our latest Biotech reports at: www.rdinvesting.com/subscribe-today/.

Biotech stocks surged immediately following Donald Trump’s Presidency. The general assumption had been that a Hillary Clinton White House would have been a major negative for biotechs and pharmaceuticals given her very public stance against the “price gouging” going on within the industry. A report by Leerink Partners in late October estimated that concerns of a win by Democratic presidential nominee Hillary Clinton triggered a $50 billion biotech selloff prior to the election.

Reuters has published on November 11, that a combination of a potential influx in foreign cash, lower corporate taxes and higher stock valuations could potentially boost merger and acquisition activity in the biotech industry. Prime acquisition targets such as Tesaro and Sarepta could see some renewed interest, according to analysts interviewed by Reuters. It could also throw a lifeline to smaller biotech firms, which on average have only 11 months of cash left to finance their research. Many biotech companies have resisted offers from companies trying to take advantage of the sector’s sell-off.

RDInvesting Takes
a Closer Look at Some Biotech Companies as We Enter 2017

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Get Your Up-To-Date
Ariad Pharmaceuticals Research
Report at www.rdinvesting.com/company/ARIA.

Ariad Pharmaceuticals’ shares gained 0.49 percent to close at $12.20 a share Tuesday. The stock traded between $12.07 and $12.28 on volume of 2.84 million shares traded. Ariad is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. On December 7th, the company released clinical data from its ALTA trial, a study of its anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, for the treatment of lung cancer. According to release, as of May 31, 2016, the data show that of patients on the 180-mg regimen with a median follow-up of 11 months, 55 percent achieved confirmed objective response as assessed by the investigator. In this arm, the median progression-free survival (PFS) was 15.6 months in this post-crizotinib setting, by both investigator and independent review committee (IRC) assessment. Shares of Ariad Pharmaceuticals have gained approximately 95.2 percent year-to-date, but have fallen roughly 13.2 percent in the past month.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Get Your Up-To-Date Amicus Therapeutics Research Report at
www.rdinvesting.com/company/FOLD.

Amicus Therapeutics’ shares declined 1.02 percent to close at $4.85 a share Tuesday. The stock traded between $4.80 and $4.95 on volume of 1.85 million shares traded. Amicus Therapeutics is focused on therapies of rare and orphan diseases. The Company has a pipeline of advanced therapies for a broad range of human genetic diseases. On November 28th, Amicus announced its planned U.S. regulatory pathway to collect additional data to support full approval of the oral precision medicine migalastat for the treatment of Fabry disease. Shares of Amicus Therapeutics have fallen approximately 50.0 percent year-to-date and are down roughly 44.6 percent in the past month.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 451509